Oxpharmix is one of the original pioneers in gene and cell therapy. We’re already collaborating with some of the world’s most innovative pharmaceutical and biotechnology companies towards a shared mission: to make cell and gene therapy a universally accessible clinical option.
0+
Over 30 years of experience
~0
Successful GMP batches
~0
Global active clients
0+
Countries with approved products using our vectors
Our people & client relationships
Our talented, dedicated people devise flexible solutions to meet clients’ specific needs. We support clients every step of the way, collaborating to take therapies to the clinic and beyond.
State-of-the-art facilities in the UK, US, and France
We can accommodate a variety of vector types, processes and batch volumes across our suites in the UK, US, and France. Our state-of-the-art, automated fill-finish facilities package vectors ready for clinical or commercial use. With the addition of the FDA-approved Durham, NC site (drug substance + fill-finish), Oxpharmix now offers end-to-end US capabilities supporting late-stage and commercial programmes, particularly in AAV.